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Population-based study of LAMA monotherapy effectiveness
compared with LABA/LAMA as initial treatment for COPD
in primary care
Miriam Barrecheguren1, Mónica Monteagudo2,3 and Marc Miravitlles 1
This epidemiological study aimed to describe and compare the characteristics and outcomes of COPD patients starting treatment
with a long-acting anti-muscarinic (LAMA) or a combination of a long-acting beta-2 agonist (LABA)/LAMA in primary care in
Catalonia (Spain) over a one-year period. Data were obtained from the Information System for the Development in Research in
Primary Care (SIDIAP), a population database containing information of 5.8 million inhabitants (80% of the population of Catalonia).
Patients initiating treatment with a LAMA or LABA/LAMA in 2015 were identified, and information about demographic and clinical
characteristics was collected. Then, patients were matched 1:1 for age, sex, FEV1%, history of exacerbations, history of asthma and
duration of treatment, and the outcomes between the two groups were compared. During 2015, 5729 individuals with COPD
started treatment with a LAMA (69.8%) or LAMA/LABA (30.2%). There were no remarkable differences between groups except for a
lower FEV1 and more previous hospital admissions in individuals on LABA/LAMA. The number of tests and referrals was low and
decreased in both groups during follow-up. For the same severity status, the evolution was similar with a reduction in exacerbations
in both groups. Treatment was changed during follow-up in up to 34.2% of patients in the LABA/LAMA and 26.3% in the LAMA
group, but adherence was equally good for both. Our results suggest that initial therapy with LAMA in monotherapy may be
adequate in a significant group of mild to moderate patients with COPD and a low risk of exacerbations managed in primary care.
npj Primary Care Respiratory Medicine  (2018) 28:36 ; doi:10.1038/s41533-018-0102-x
INTRODUCTION
The aim of pharmacological treatment in chronic obstructive
pulmonary disease (COPD) is to reduce symptoms, decrease the
frequency and severity of exacerbations and improve exercise
tolerance.1 Previous studies have demonstrated the efficacy of
long-acting bronchodilators (LABD) in improving lung function,
respiratory symptoms, exacerbations, exercise capacity and quality
of life2 and constitute the cornerstone of COPD treatment.1,3,4
Among LABD, long-acting anti-muscarinic agents (LAMA) have
shown greater efficacy in the prevention of exacerbations
compared to long-acting β2-agonists (LABA),5,6 and therefore,
guidelines recommend the use of LAMA over LABA as the initial
treatment in COPD.1,3,4
In recent years, new treatments for COPD have been launched,
most being LABD, inhaled corticosteroids (ICS) and combinations
of the two, with the objective of improving patient outcomes in
COPD. Recent studies have suggested that dual treatment with a
LAMA and a LABA results in greater bronchodilation and improved
symptoms and health status compared to a LABD in mono-
therapy.7,8 However, most studies assessing the efficacy of double
bronchodilation compared with monotherapy have included
moderate to severe patients with dyspnoea according to the
modified Medical Research Council (mMRC) ≥ 2 scale,2,7,8 exclud-
ing milder patients who may not present a significant improve-
ment with the addition of a second LABD. In addition, there is a
lack of follow-up studies in real life in primary care investigating
the effectiveness of LABD and its combination with other agents
in the usual clinical practice. The use of large population-based
databases may help to increase the knowledge on real-life use of
bronchodilator treatment in primary care. Therefore, the objective
of this study was to describe the characteristics and outcomes of
COPD patients starting inhaled treatment with a LAMA or a
combination of LABA/LAMA in primary care in Catalonia (Spain)
over a 1 year period.
RESULTS
During 2015, we identified 5729 individuals with a codified
diagnosis of COPD who started treatment with either a LAMA
(4001 or 69.8%) or LAMA/LABA (1728 or 30.2%). These patients
constituted the population of our study. Among the patients
receiving a LAMA/LABA, 68.3% received the combination in the
same inhalation device.
Baseline characteristics
In total, 76.9% were men with a mean age of 66.3 (SD 11.1) years,
with no differences between the LAMA or LAMA/LABA groups.
The patients were diagnosed a mean of 3.3 (4.9) years before
inclusion, with significant differences between groups [3.9 (5.3)
years for the LABA/LAMA group vs. 3.1 (4.7) years for the LAMA
patients, p < 0.001]. The most frequent comorbidities were
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hypertension (57.7%), diabetes mellitus (25.2%), dyslipidemia
(50.9%) and depression (18.3%).
Spirometry result with a FEV1 was available in only 40% of the
patients. Individuals treated with a combination of two bronch-
odilators presented more severe disease, with a lower FEV1 %
(56.9% (18.5) vs. 65.0% (18.7), p < 0.001) and included a greater
number of patients classified as GOLD 3 and GOLD 4. Distribution
by phenotypes was similar between the two groups. Patients
treated with double bronchodilation tended to have more
hospital admissions for all causes during the previous year but
not for respiratory causes, although numbers were very small. The
baseline characteristics of the cohort and by treatment group are
presented in Table 1.
Longitudinal analysis: matching sub-cohort
For the longitudinal analysis we identified 1897 (33%) individuals
who fulfilled the criteria for the diagnosis of COPD (Fig. 1). Finally,
of these, matching was possible for 524 patients from each
treatment group.
As expected, there were no differences in the baseline
characteristics between groups, although the time from diagnosis
to treatment was longer in the combined group (3.7 (5.1) years vs.
2.8 (4.3) years, p= 0.002) (Table 2).
During the 12-month follow-up, only 22.7% of patients in the
LAMA group underwent spirometry. The number of chest X-rays
and computerised tomography (CT) lung studies also significantly
decreased in the LAMA group (Table 2). This group also showed a
Table 1. Baseline characteristics of the patients studied
Total N= 5729 Patients starting on LAMA N= 4001 Patients starting on LABA/LAMA N=
1728
p-value
Sex (men) 4406 (76.9) 3043 (76.1) 1363 (78.9) 0.02
Age, years 66.25 (11.1) 66.42 (11.1) 65.84 (11.1) NS
Years from diagnosis 3.33 (4.9) 3.08 (4.7) 3.91 (5.3) <0.001
BMI (Kg/m2) 29.14 (5.3) 29.04 (5.2) 29.36 (5.4) NS
Smoking history (n,%) NS
Never smoker 1115 (19.5) 792 (19.8) 323 (18.7)
Active smoker 2232 (39) 1586 (39.6) 646 (37.4)
Former smoker 2318 (40.5) 1588 (39.7) 730 (42.2)
Unknown 64 (1.1) 35 (0.9) 29 (1.7)
Phenotype (n, %) NS
ACO 183 (3.2) 128 (3.2) 55 (3.2)
Non exacerbator 1303 (22.7) 890 (22.2) 413 (23.9)
Exacerbator 4243 (74.1) 2983 (74.6) 1260 (72.9)
Comorbidities
Asthma 262 (4.6) 184 (4.6) 78 (4.5) NS
Bronchiectasis 233 (4.1) 180 (4.5) 53 (3.1) 0.01
OSA 331 (5.8) 232 (5.8) 99 (5.7) NS
Ischaemic heart disease 808 (14.1) 570 (14.2) 238 (13.8) NS
Heart failure 483 (8.4) 306 (7.6) 177 (10.2) 0.001
Atrial fibrilation 593 (10.4) 411 (10.3) 182 (10.5) NS
Hypertension 3307 (57.7) 2303 (57.6) 1004 (58.1) NS
Diabetes mellitus 1443 (25.2) 1002 (25) 441 (25.5) NS
Dyslipidemia 2915 (50.9) 2069 (51.7) 846 (49) 0.05
Depression 1049 (18.3) 746 (18.6) 303 (17.5) NS
Osteoporosis 396 (6.9) 290 (7.2) 106 (6.1) NS
GERD 299 (5.2) 212 (5.3) 87 (5) NS
Complementary tests
Spirometries with FEV1 2271 (39.6) 1584 (39.6) 687 (39.8) NS
FEV1 % 62.5 (18.9) 65.0 (18.6) 56.9 (18.5) <0.001
Severity N (%) (n= 2271) <0.001
Gold 1 354 (15.6) 296 (18.7) 58 (8.4)
Gold 2 1415 (62.3) 1013 (64) 402 (58.5)
Gold 3 424 (18.7) 236 (14.9) 188 (27.4)
Gold 4 78 (3.4) 39 (2.5) 39 (5.7)
Exacerbations during the previous 12 months, n (%) NS
0 exacerbations 2685 (46.9) 1871 (46.7) 814 (47.1)
1 exacerbations 1741 (30.4) 1240 (31.0) 501 (28.9)
≥2 exacerbations 1303 (22.7) 890 (22.2) 413 (23.9)
Hospital admission during the previous 12 months, n (%)
Total 449 (7.8) 294 (7.3) 155 (9) 0.03
Respiratory hospital admission 22 (0.4) 13 (0.3) 9 (0.5) NS
Data are expressed as mean (SD) unless specified otherwise
BMI body mass index, ACO asthma COPD overlap, OSA obstructive sleep apnoea, GERD gastrooesophageal reflux disease, FEV1 forced expiratory volume in 1 s,
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significant reduction in the number of patients presenting an
exacerbation compared to the previous year (−13.9%, 95% CI:
−19.9;−7.9; p < 0.001) and in the mean number of exacerbations
(−0.3, 95% CI: −0.4; −0.1; p < 0.001). The percentage of patients
consulting with a nurse or being referred to a specialist also
significantly decreased in the LAMA group during the one-year
follow-up.
Patients treated with a LABA/LAMA also showed a reduction in
the number of spirometries chest X-rays and CT scans performed
(Table 2). This group showed a reduction in the percentage of
patients presenting an exacerbation (−8.6%, 95% CI: −14.6; −2.6;
p < 0.001), and in the mean number of exacerbations (−0.2, 95%
CI: −0.3; −0.1; p < 0.001). In addition, fewer patients consulted a
nurse or were referred to a pulmonologist compared to the year
before initiating treatment (−21.2%, 95% CI: −25.5; −16.8; p <
0.001).
On comparing the two groups, patients treated with a LAMA
showed a greater reduction in the number of chest X-rays
performed and the number of patients with any exacerbation
(percentage difference −5.3%, 95% CI: −9.2; −1.5; p < 0.001).
Patients receiving LAMA were less frequently referred to the
pulmonologist (mean difference 7.6%, 95% CI: 3.1; 12.2; p < 0.05).
Changes in treatment and adherence during follow-up
A total of 439 (83.8%) of the patients initially treated with a LAMA
continued receiving this treatment over the 1 year follow-up,
although only 73.7% were treated with LAMA alone. The
percentage of patients who continued with a LABA/LAMA
combination was 65.8% (Table 3).
We observed good adherence to treatment (proportion of days
covered [PDC] > 80%) in 71% of patients initiating with a LAMA
and 66.6% for LABA/LAMA. In the LABA/LAMA group, adherence
was similar for patients treated with one or two devices (67.1 and
65.7%, respectively).
Regarding changes in treatment, in the LAMA group, treatment
was escalated in 11.6% during the year of follow-up (7.4% to
LABA/LAMA and 5.5% to triple therapy), 4.2% were switched to
LABA/ICS and in 5.5% the treatment was de-escalated to no
inhaled treatment.
In the LABA/LAMA group, treatment was escalated to triple
therapy in 6.3%, being de-escalated to LABD in monotherapy in
15.3% (8.4% LAMA and 6.9% LABA), 4.8% changed to LABA/ICS
and 6.5% to no inhaled therapy (Table 4) (Fig. 1).
Changes in treatment differed according to severity. In the
LAMA group less severe patients (GOLD 1 and 2) tended to
continue on a LAMA (83.9% of GOLD 1 and 75.4% of GOLD 2). The
most frequent change of treatment was escalation to LABA/LAMA
or discontinuation of all treatment. In the LABA/LAMA group, only
two thirds of GOLD 1 and 2 patients continued with the same
treatment. Patients were frequently de-escalated to one LABD
(23.7% of GOLD 1 and 26.1% of GOLD 2) or no maintenance
therapy (Table 4).
Up to 13.5% of GOLD 3 patients in the LAMA group were
escalated to LABA/LAMA, while GOLD 4 were more frequently
escalated to triple therapy or were switched to LABA/ICS. In the
LABA/LAMA group, GOLD 4 patients were switched to triple
therapy (5.9%) and more frequently to LABA/ICS (17.6%).
DISCUSSION
The results of this study show that COPD patients starting
treatment with a LAMA or a LABA/LAMA in the primary care
setting had no remarkable differences in clinical characteristics
except in regard to disease severity; patients initially treated with
the combination of bronchodilators had a lower FEV1 and a
greater number of previous hospital admissions. The number of
diagnostic tests and referrals was low in the two groups and
decreased during the one-year follow up, especially in those
receiving a LAMA. After performing a matching analysis, we
observed that for the same severity status, the evolution was
similar for individuals treated with a LAMA or LABA/LAMA. In up to
34.2% of patients in the LABA/LAMA group and 26.3% in the
LAMA group a change was made in treatment during follow-up,
but the adherence was equally good in both treatment schedules.
During the year of the study, 5729 COPD individuals started
treatment with either a LAMA or a LABA/LAMA. Among them,
1897 had confirmed COPD (coded for COPD plus airflow
obstruction and smoking history). In Catalonia, a region with
approximately 7.5 million inhabitants, a recent study also carried
out using the SIDIAP (Information System for the Development of
Research in Primary Care) database9 found that approximately
7000 individuals were diagnosed with COPD every year between
Fig. 1 Changes in the treatment pattern at 12 months of follow-up compared to baseline. Continous arrow: step-up or equivalent treatment;
dashed arrow: step-down treatment. LABA long-acting beta-2 agonist, LAMA long-acting anti-muscarinic, ICS inhaled corticosteroid
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2007 and 2012, but only 11.3 and 3.7% were initially treated with a
LAMA or a LABA/LAMA combination in 2012, respectively,
suggesting that the use of LABD has increased in recent years.
Interestingly, almost two thirds of the patients started with a
LAMA and only one third with a LABA/LAMA combination, which
is consistent with data from the UK where the most frequent initial
treatment for COPD in primary care is a LAMA.10
In our study, only 40% of the patients had undergone
spirometry with an available FEV1 measurement, which is
consistent with previous data from primary care in our coun-
try9,11,12 and in other European countries.13–15 Moreover, along
the 12 months after the initiation of the therapy, a follow-up
spirometry was performed in only one quarter of the patients in
each group.
We found that patients with a codified diagnosis of COPD
treated with the combination of bronchodilators had a lower FEV1
and more previous hospital admissions for all causes. However, we
found no differences in other relevant clinical characteristics, such
as phenotype or the number of previous out-patient exacerba-
tions. Furthermore, previous hospital admissions for respiratory
causes were similar, and very low, in both groups. We observed
the same results when we analyzed only patients with confirmed
COPD (data not shown).
To avoid biases due to different degree of severity, we
performed a matching analysis to compare the evolution of
COPD patients by group therapy. Firstly, in order to exclude
asthma or other respiratory diseases possibly miscodified as COPD
as far as possible, we selected only patients who had a history of
smoking and a FEV1/FVC < 0.7. Secondly, we matched individuals
from both treatment groups by age, sex, FEV1, previous history of
exacerbations, history of asthma and duration of treatment during
the first 12 months of follow-up. After matching, we found that
the evolution of patients treated with a LAMA or a LABA/LAMA did
not significantly differ. The assessments performed during follow-
up were similar for both groups with a low number of tests
performed, visits to the nurse and referrals, although chest X-rays
and referrals to the chest physician were even less frequent in the
LAMA group.
Patients in both groups presented a significant reduction in the
number of exacerbations after the initiation of treatment,
consistent with previous clinical trials.8,16 Interestingly, in the
LAMA group there was a greater reduction in the number of
patients presenting an exacerbation, compared to patients initially
receiving two bronchodilators. In contrast with these results,
previous randomised control trials have shown that a LABA/LAMA
combination can improve exacerbation outcomes in comparison
to monotherapy. The Spark study,16 which was designed to
evaluate the effect of dual bronchodilator treatment on exacer-
bations, reported a reduced annual rate of moderate or severe
exacerbations with indacaterol/glycopyrronium compared to
glycopyrronium alone. These differences in outcomes are
probably due to the population studied. Spark included severe
COPD individuals with a FEV1 < 50% and at least one exacerbation
in the previous year, while our study population included less
severe patients with a majority of GOLD 2 and 45% of patients
without any exacerbation in the previous year.
Changes in treatment were more frequent in the LABA/LAMA
group. The most frequent change was de-escalation to a LABA or a
LAMA (15.3%) followed by no treatment. This was more common
in milder patients, while GOLD 4 patients tended to continue with
the combination of bronchodilators. In comparison, changes in
treatment were slightly less frequent in the LAMA group, with the
most frequent change being escalation to a LABA/LAMA
combination or triple therapy (12.9%), while 6.8% switched to a
LABA or LABA/ICS. An analysis of the Pharmo database in the
Netherlands found more frequent changes in treatment in
patients on LAMAs, with persistence rates at 1, 2, and 3 years of
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most patients were changed to ICS/LABA. Wurst et al.18 also
observed a lower persistence to newly initiated LAMA, with 10% of
patients receiving the addition of other therapies or 9% being
switched from LAMA mainly to LABA/ICS and with many patients
discontinuing therapy. Another study that described the changes
to triple therapy found that starting with a LAMA was one of the
least frequent schedules and represented only 9.5% among all the
patients finally receiving triple therapy.19
In our population, adherence was good and did not significantly
differ between the LAMA (71%) and LABA/LAMA groups (66.6%).
Other studies analysing the persistence of treatment with LAMAs
in Spain have described similar results. One study only included
individuals treated with aclidinium or tiotropium and observed an
initially high persistence with LAMA that progressively decreased
to 50% after 1 year of follow-up.20 Izquierdo et al.21 conducted
another population-based study in Castile-La Mancha (Spain) and
observed a high rate of compliance (from 80 to 120%) in patients
treated with LAMAs.
The main limitation of the present study is the lack of data on
dyspnoea (mMRC) or the COPD assessment test, which may be
implicated in therapeutic decision making. However, an observa-
tional study aimed at identifying predictors of physician treatment
choice in primary care in the UK observed that the mMRC score
was a weak predictor of therapeutic choice,22 and had no impact
on the treatment modifications to triple therapy.19 Other
limitations inherent to database studies are diagnostic and
miscoding biases. To minimise these biases we only included
individuals with confirmed COPD (codified diagnosis plus smoking
history and FEV1/FVC < 0.7) in the longitudinal matched analysis.
In contrast, the main strength of our study is the large coverage of
the database, including more than 80% of the population of
Catalonia (Spain), thereby ensuring the representativeness of our
data.
In conclusion, our study suggests that Primary Care physicians
in Catalonia more frequently prescribe a LABA/LAMA combination
instead of a LAMA for the most severe COPD patients, consistent
with guideline recommendations.1,3,4,23 Most patients initiating
treatment with a LAMA remain stable during follow-up and
frequently continue on the same treatment over time. In contrast,
patients initially treated with a LABA/LAMA combination are more
likely to be switched to other treatment schedules, particularly de-
escalation to a single LABD. This was more frequently observed in
GOLD 1 and 2 patients, which suggests unnecessary over-
treatment in milder stages of the disease. Adherence to treatment
was high in both treatment groups. Our results suggest that initial
therapy with LAMA in monotherapy may be adequate for a
significant group of mild to moderate patients with COPD and a
low risk of exacerbations managed in primary care.24
METHODS
This was an epidemiological study with retrospective analysis of long-
itudinal follow-up data that aimed to compare the characteistics of the
COPD patients initiating treatment with a LAMA or a combination of
LAMA/LABA in primary care in 2015 and their clinical evolution over a 12-
month follow-up period.
The data for this study was obtained from the SIDIAP database, a
computerised database containing anonymized patient records for the 5.8
million people registered in one of the 279 primary care centres of the
Catalan Health Institute (approximately 80% of the population of
Catalonia).25 All the general practitioners in the Catalan Public Health
Service use the same eCAP software to record the clinical information of
their patients. Health professionals gather this information using ICD-10
codes and structured forms designed for the collection of variables such as
smoking history or body mass index or test results such as spirometries.
SIDIAP combines information from the electronic medical records with
data from other databases and registers including the Pharmacy Register
(medication dispensed in pharmacies) and the National Death registry. The
study was approved by the Research and Ethics Committee of the IDIAP
Jordi Gol Institute of Research In Primary Care (Barcelona, Spain).
Study population
For the first objective of the comparison of characteristics of COPD patients
initiating treatment with a LAMA or LAMA/LABA, we selected all individuals
older than 40 years who started treatment with either a LAMA or a
combination of a LAMA and a LABA (separately or in one device) during
2015 and were diagnosed with COPD at or before the date of the first
prescription of maintenance therapy. Patients were required to have at
least 2 years of continuous data (1 year before and 1 year after the first
prescription of maintenance therapy).
For the second objective, comparison of the clinical evolution and
changes in treatment over a 12-month follow-up period in patients initially
treated with a LAMA or a LABA/LAMA, only patients with a confirmed
diagnosis of COPD defined as a history of smoking and spirometry with
FEV1/FVC < 0.7 were included, as in previous studies.9,21 In addition,
patients were matched 1:1 for age, sex, FEV1%, previous history of
exacerbations, history of asthma and duration of treatment in order to
account for the possible differences in clinical characteristics and the
severity of patients initiating treatment with a LAMA in monotherapy or
with two bronchodilators (Fig. 2).
Table 4. Changes in treatment pattern according to severity (GOLD stages) during the 12-month follow-up in patients in both groups matched for
age, sex, FEV1%, previous history of exacerbations, history of asthma and duration of treatment

















LAMA 386 (73.7) 47 (83.9) 245 (75.4) 78 (66.1) 16 (64) 44 (8.4) 6 (14.3) 31 (9.3) 7 (5.3) 0
LABA 7 (1.3) 0 5 (1.5) 2 (1.7) 0 36 (6.9) 1 (2.4) 30 (9) 5 (3.8) 0
ICS 5 (1) 1 (1.8) 2 (0.6) 1 (0.8) 1 (4) 7 (1.3) 1 (2.4) 4 (1.2) 2 (1.5) 0
LABA/LAMA 39 (7.4) 3 (5.4) 20 (6.2) 16 (13.6) 0 345 (65.8) 28 (66.7) 209 (62.8) 95 (72) 13 (76.5)
LABA/ICS 22 (4.2) 1 (1.8) 12 (3.7) 5 (4.2) 4 (16) 25 (4.8) 1 (2.4) 13 (3.9) 8 (6.1) 3 (17.6)
LAMA/ICS 7 (1.3) 0 4 (1.2) 3 (2.5) 0 0 0 0 0 0
LAMA/LABA/ICS 29 (5.5) 1 (1.8) 17 (5.2) 8 (6.8) 3 (12) 33 (6.3) 2 (4.8) 20 (6) 10 (7.6) 1 (5.9)
No treatment 29 (5.5) 3 (5.4) 20 (6.2) 5 (4.2) 1 (4) 34 (6.5) 3 (7.1) 26 (7.8) 5 (3.8) 0
Data are expressed as n (%)
LABA long-acting beta-2 agonist, LAMA long-acting anti-muscarinic, ICS inhaled corticosteroid
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Measurements
Severity was assessed based on GOLD stages in the patients for whom a
FEV1 value was available (stage 1 mild, FEV ≥ 80% predicted, stage 2
moderate 50% ≤ FEV1 < 80% predicted; stage 3 severe, 30% ≤ FEV1 < 50%
predicted; stage 4 very severe FEV < 30% predicted).1 Exacerbations were
identified by diagnostic codes and by treatment (patients receiving
antibiotics and/or oral corticosteroids in the absence of another codified
infectious event such as tonsillitis or urine infection).
Patients with two or more exacerbations during the year before
initiation of therapy were classified as having a frequent exacerbator
phenotype, while those with a previous history of asthma were included in
the asthma COPD overlap (ACO) phenotype, and the remaining COPD
patients were considered non exacerbators.
A change in treatment was defined as the registration of a new LABD or
ICS for at least 60 days and after 2 months following the initiation of
treatment with or without new billing of the treatment of interest.
Statistical analysis
A descriptive analysis of the initial COPD population identified by a
diagnostic code was performed. For qualitative variables, absolute
frequencies and corresponding percentages were calculated. Quantitative
variables with a normal distribution were described by mean and standard
deviation, while those that did not follow a normal distribution were
described using the median and 25–75 percentiles.
Categorical variables were compared using the Chi-square or Fisher
exact test when applicable. Quantitative variables were compared using
the T-test or Mann–Whitney U.
For the follow-up study, the two study sub cohorts were constructed
based on a 1:1 matching using the greedy-matching algorithm (without
replacement) and the propensity score. We calculated the mean or
percentage differences for the different variables between the 12-month
follow-up after the first prescription of maintenance therapy and the year
before this prescription for both groups independently: those initiating
with a LAMA or a LABA/LAMA, followed by calculation of the mean or
percentage differences between the two groups.
A logistic regression model was used to establish the propensity score to
predict the probability of a patient being treated with a LAMA or LABA/
LAMA.
The PDC was used to study therapeutic adherence, A patient was
considered to be adherent to treatment when the relation between the
proportion of the billed doses of pharmacy and the number of days
covered according to the labelling of the product (or PDC) was greater
than 0.80.
The matching analyses were performed using the statistical software
package Stata/SE version 14 for Windows (Stata Corp. LP, College Station,
Texas, US), and SPSS version 22 (SPSS Inc., Chicago, IL, USA) was used for
the remaining statistical analyses.
DATA AVAILABILITY
The data that support the findings of this study are available from IDIAP Jordi Gol but
restrictions apply to the availability of these data, which were used under license for
the current study, and so are not publicly available. Data are however available from
the authors upon reasonable request and with permission of IDIAP Jordi Gol.
ACKNOWLEDGEMENTS
The study was supported by an unrestricted grant from Gebro Pharma. Miriam
Barrecheguren is the recipient of a Rio Hortega contract in the 2017 Strategic Action
Health Call from the Instituto de Salud Carlos III for the years 2018–2019.
AUTHOR CONTRIBUTIONS
M.M., M. Monteagudo and M.B. designed the study. M. Monteagudo prepared the
database and performed the analyses. All the authors were involved in the study
methodology and interpretation of results. M.B. wrote the first draft. All the authors
commented on the manuscript and contributed to the final version.
ADDITIONAL INFORMATION
Competing interests: M.B. has received speaker fees from Grifols, Menarini, GSK and
consulting fees from Novartis and Gebro Pharma. M.M. has received speaker fees
from Boehringer Ingelheim, Chiesi, Cipla, Menarini, Rovi, Grifols and Novartis, and
consulting fees from Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Gebro Pharma,
CSL Behring, Novartis and Grifols. The other author declares no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims
in published maps and institutional affiliations.
REFERENCES
1. Vogelmeier, C. F. et al. Global Strategy for the Diagnosis, Management, and
Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive
Summary. Arch. Bronconeumol. 53, 128–149 (2017).
2. Miravitlles, M., Anzueto, A. & Jardim, J. Optimizing bronchodilation in the pre-
vention of COPD exacerbations. Respir. Res. 18, 125 (2017).
3. Miravitlles, M. et al. Spanish COPD guidelines (GesEPOC) 2017. Pharmacological
treatment of stable chronic obstructive pulmonary disease. Arch. Bronconeumol.
53, 324–335 (2017).
4. Miravitlles, M. et al. A review of national guidelines for management of COPD in
Europe. Eur. Respir. J. 47, 625–637 (2016).
5. Decramer, M. L. et al. Once-daily indacaterol versus tiotropium for patients with
severe chronic obstructive pulmonary disease (INVIGORATE): a randomised,
blinded, parallel-group study. Lancet Respir. Med. 1, 524–533 (2013).
6. Vogelmeier, C. et al. Tiotropium versus salmeterol for the prevention of exacer-
bations of COPD. N. Engl. J. Med. 364, 1093–1103 (2011).
7. Bateman, E. D. et al. Dual bronchodilation with QVA149 versus single broncho-
dilator therapy: the SHINE study. Eur. Respir. J. 42, 1484–9412 (2013).
8. Miravitlles, M., Urrutia, G., Mathioudakis, A. G. & Ancochea, J. Efficacy and safety of
Tiotropium and Olodaterol in COPD: a systematic review and meta-analysis.
Respir. Res. 18, 196 (2017).
9. Barrecheguren, M. et al. Treatment patterns in COPD patients newly diagnosed in
primary care. A population-based study. Respir. Med. 111, 47–53 (2016).
10. Price, D. et al. First maintenance therapy for COPD in the UK between 2009 and
2012: a retrospective database analysis. NPJ Prim. Care Respir. Med. 26, 16061
(2016).
11. Monteagudo, M. et al. Variability in the performing of spirometry and its con-
sequences in the treatment of COPD in primary care. Arch. Bronconeumol. 47,
226–233 (2011).
12. Miravitlles, M. et al. Use of spirometry and patterns of prescribing in COPD in
primary care. Respir. Med. 101, 1753–1760 (2007).
13. Melbye, M. et al. Asthma, chronic obstructive pulmonary disease or both?
Diagnostic labeling spirometry in primary care patients aged 40 years or more.
Int. J. Chron. Obstruct. Pulmon. Dis. 6, 597–603 (2011).
14. Arne, M. et al. How often is diagnosis of COPD confirmed with spirometry? Respir.
Med. 104, 550–556 (2010).
15. Walker, P. P., Mitchell, P., Diamantea, F., Warburton, C. J. & Davies, L. Effect of
primary-care spirometry on the diagnosis and management of COPD. Eur. Respir.
J. 28, 945–952 (2006).
16. Wedzicha, J. A. et al. Analysis of chronic obstructive pulmonary disease exacer-
bations with the dual bronchodilator QVA149 compared with glycopyrronium
Fig. 2 Flowchart of the patients included in the study. SIDIAP
information system for research in primary care, COPD chronic
obstructive pulmonary disease, LABA long-acting beta-2 agonist,
LAMA long-acting anti-muscarinic, Hx history, FEV1 forced expira-
tory volume in 1 s, FVC forced vital capacity
Effectiveness of LAMA compared to LAMA/LABAy
M Barrecheguren et al.
7
Published in partnership with Primary Care Respiratory Society UK npj Primary Care Respiratory Medicine (2018)  36 
and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet
Respir. Med. 1, 199–209 (2013).
17. Penning van Beest, F., van Herk-Sukel, M., Gale, R., Lammers, J. W. & Herings, J.
Three-year dispensing patterns with long-acting inhaled drugs in COPD: a
database analysis. Respir. Med. 105, 259–265 (2011).
18. Wurst, K. E., Laurent, S., Mullerova, H. & Davis, K. J. Characteristics of patients with
COPD newly prescribed a long-acting bronchodilator: a retrospective cohort
study. Int J. Chron. Obst. Pulm. Dis. 9, 1021–1031 (2014).
19. Brusselle, G. et al. The inevitable drift to triple therapy in COPD: an analysis of
prescribing pathways in the UK. Int J. Chron. Obst. Pulm. Dis. 10, 2207–2217 (2015).
20. Monteagudo, M. et al. Characteristics of COPD patients initiating treatment with
aclidinium or tiotropium in primary care in Catalonia: a population-based study.
Int J. Chron. Obst. Pulm. Dis. 12, 1145–1152 (2017).
21. Izquierdo, J. L., Paredero, J. M. & Piedra, R. Relevance of dosage in adherence to
treatment with long-acting anticholinergics in patients with COPD. Int J. Chron.
Obst. Pulm. Dis. 11, 289–293 (2016).
22. Gruffydd-Jones, K. et al. Changes in initial COPD treatment choice over time and
factors influencing prescribing decisions in UK primary care: a real-world study.
NPJ Prim. Care Respir. Med. 26, 16002 (2016).
23. Thomas, M., Halpin, D. & Miravitlles, M. When is dual bronchodilation indicated in
COPD? Int J. Chron. Obst. Pulm. Dis. 12, 2291–2305 (2017).
24. Decramer, M. et al. New horizons in early stage COPD – Improving knowledge,
detection and treatment. Respir. Med. 105, 1576–1587 (2011).
25. Bolíbar, B. et al.SIDIAP database: electronic clinical records in primary care as a
source of information for epidemiologic research. Med. Clin. 138, 617–621 (2012).
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in anymedium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly
from the copyright holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
© The Author(s) 2018
Effectiveness of LAMA compared to LAMA/LABAy
M Barrecheguren et al.
8
npj Primary Care Respiratory Medicine (2018)  36 Published in partnership with Primary Care Respiratory Society UK
